13 October 2025

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

Q3 2025 Trading Update and Grant of Options

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a Q3 2025 trading update (for the nine months to 30 September 2025) which reaffirms continued strong progress.

Key Highlights*:

·    Sales +30% to £1.97m (2024: £1.52m)

·    Gross Profit +21% to £1.06m to (2024: £874k)

·    Gross Profit margin at 54%** (2024: 58%)

·    Cash balance robust, with sufficient funding to deliver business plan

·    Current forward order book at record levels

*Unaudited figures

**Due to a small stock write down

Steen Andersen, CEO of ProBiotix, commented: "We are very pleased with the growth which is being achieved at ProBiotix, resulting in another period of record sales (with the 9 month period showing revenues in excess of the previous full year) and a solid level of new enquiries as we scale the business. The recent well received launch of new products, coupled with the sell through of products by our increasing number of worldwide distributors, augurs well for our future growth prospects.

"Driven by the current momentum we remain comfortably on track to reach our long term strategic objectives, and look forward to providing further updates on our progress in the months ahead."  

Grant of Options

The board has today issued 700,000 options to three members of the senior management team, exercisable at 9.5p per share. The Options have been issued on the same terms as existing options and may be exercised within 10 years from the date of their grant, subject to the satisfaction of commercially oriented performance criteria, which includes significant revenue targets.  At the same time 500,000 options have lapsed on the retirement of one of the management team.

For further information, please contact:

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a singular approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.